Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Ontology highlight
ABSTRACT: To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving therapy with regorafenib and XmAb20717 (also known as vudalimab). ctDNA is genetic material from tumor cells that can be found and measured in the blood
DISEASE(S): Rectum Cancer,Rectal Neoplasms,Colon Cancer,Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 63177 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA